- CpG oligonucleotides, acting as synthetic immunostimulatory agents that activate Toll-like receptor 9 (TLR9), are emerging as critical components in modern immunotherapy strategies, particularly in oncology and vaccine adjuvant development due to their ability to enhance innate and adaptive immune responses
- The growing demand for CpG oligonucleotide therapeutics is primarily fueled by the increasing prevalence of cancer, rising interest in personalized medicine, and ongoing advancements in oligonucleotide synthesis technologies enabling greater stability and efficacy
- North America dominated the CpG oligonucleotide therapeutics market with the largest revenue share of 43% in 2024, characterized by strong biopharmaceutical R&D ecosystem, robust clinical trial activity, and significant funding from both private and public sectors, especially in the U.S., which is witnessing a surge in immunotherapy-based oncology pipelines and CpG-adjuvanted vaccine initiatives
- Asia-Pacific is expected to be the fastest growing region in the CpG Oligonucleotide Therapeutics market during the forecast period due to expanding biotechnology sectors, increasing government funding for immunological research, and growing patient access to advanced therapies
- Oncology segment dominated the CpG oligonucleotide therapeutics market with a market share of 45.5% in 2024, driven by its established reputation for security and ease of retrofit into existing door setups
